# A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs

> **NCT07483684** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 142 (estimated)

## Conditions studied

- HER2 IHC3+ Advanced Colorectal Cancer

## Interventions

- **DRUG:** TQB2102 Injection
- **DRUG:** Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets

## Key facts

- **NCT ID:** NCT07483684
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2027-08
- **Final completion:** 2028-12
- **Target enrollment:** 142 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07483684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07483684, "A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07483684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*